Head-to-head evidence
Anti-CD33 CAR T-cells vs Gemtuzumab Ozogamicin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
Anti-CD33 CAR T-cells
Developed by iCell Gene Therapeutics
NCT01864902 · Phase 1/2 · status unknown
This was a small, single-arm, open-label study with no comparator group, designed primarily to assess safety of this cell therapy in a heavily pretreated leukemia population. Results have not yet been posted.
Next expected readout: September 2028 · NCT05672147 (registry estimate)
Gemtuzumab Ozogamicin
Marketed by Pfizer
NCT00052299 · Phase 3 · completed
The trial was randomized and actively controlled, with 472 participants, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT05955261 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anti-CD33 CAR T-cells's landscape · Gemtuzumab Ozogamicin's landscape